Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Amends OTC Oral Sodium Phosphate Labeling, Warns Of Risks

This article was originally published in The Tan Sheet

Executive Summary

FDA recommends consumers not use OTC oral sodium phosphate for bowel cleansing and says it will amend labeling for the products because of a risk of serious kidney injuries
Advertisement

Related Content

OTC Monograph Reform Could ‘Unlock’ Innovations In Three Years
OTC Monograph Reform Could ‘Unlock’ Innovations In Three Years
OTC Monograph Reform Could ‘Unlock’ Innovations In Three Years
In Brief
FDA’s Agenda Slates September For Cough/Cold Proposal, Sunscreen Rule
FDA Nonprescription Office Adding Staff To Focus On Monograph Work
New Products In Brief
CB Fleet voluntarily recalls OTC OSP
Petition Urges FDA To Take Oral Sodium Phosphate Laxatives Off OTC Market
Law firm cites Phospho-Soda package change

Topics

Advertisement
UsernamePublicRestriction

Register

PS102410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel